AMRN vs BIIB: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BIIB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMRN and BIIB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMRN and BIIB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amarin Corporation is a pharmaceutical company whose business is dominated by one product, VASCEPA (marketed as VAZKEPA in Europe), the brand name for icosapent ethyl, a highly purified omega-3 prescription therapy derived from fish oil. VASCEPA lowers triglycerides and, based on a cardiovascular outcomes trial, is used to reduce the risk of cardiovascular events in certain statin-treated patients with elevated triglycerides. Amarin makes money by selling VASCEPA in the United States and by licensing and collecting royalties from partners who commercialize the drug in other regions. Because the company depends so heavily on a single molecule, its fortunes track VASCEPA's prescription volumes, pricing, and competitive dynamics rather than a diversified portfolio.

Full AMRN guide

Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases.

Full BIIB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMRN drivers: Stabilizing the US VASCEPA franchise; International expansion through partners.
• BIIB drivers: Leqembi Alzheimer's ramp; Rare-disease and new-product portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The overriding risk is single-product concentration: Amarin's fortunes rest almost entirely on VASCEPA, so any pressure on that franchise flows straight to the company. For BIIB, the legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMRN if you believe its drivers more; BIIB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMRN and BIIB guides.

AMRN. These figures are approximate, tied to the asOf date, and should be verified against Amarin's latest filings before acting. For a company in revenue transition, headline multiples are less meaningful than the trajectory of US branded volumes, international royalty growth, and cash generation. A large cash balance relative to market value is part of the value case, but cash can be consumed if the business does not stabilize, so watch the cash-flow trend rather than any single quarter.

BIIB. Biogen trades at a low double-digit forward earnings multiple, well below the drug-manufacturer industry median, reflecting a shrinking legacy base and turnaround uncertainty. Q1 2026 earnings beat expectations on cost discipline and Leqembi momentum, but management still guides full-year revenue down a mid-single-digit percentage. The valuation prices in doubt that new launches will outrun legacy erosion.

Headline figures (approximate, Jul 2026): AMRN shows total net revenue (q1 2026) ~$45 million reported, up modestly year over year per the company (verify live), revenue mix Mostly US VASCEPA product sales plus growing licensing and royalty income from international partners, profitability Operating and net losses reported in Q1 2026 but narrowing sharply as costs were cut, cash flow Company reported positive cash flow in consecutive quarters and targets full-year 2026 positive cash flow; BIIB shows revenue (ttm) ~$9.7B, q1 2026 revenue ~$2.5B (up ~2% YoY), q1 2026 non-gaap eps ~$3.57, market cap ~$29B.

AMRN and BIIB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMRN and BIIB exposure against your real portfolio. It is not an investment adviser.